A Study to Compare the Effectiveness of Rivaroxaban and Warfarin for Preventing Blood Clots in Adults With Idiopathic Membranous Nephropathy

What this Trial Is About

Researchers are evaluating the use of rivaroxaban for preventing blood clots in patients with idiopathic membranous nephropathy IMN, a kidney condition associated with a high risk of thrombosis. This prospective, single-center, randomized controlled trial compares rivaroxaban to warfarin in patients at high risk of thrombosis but low risk of bleeding. The study aims to determine which drug is more effective in reducing blood clot events in this population over six months. Participants are randomly assigned to receive either rivaroxaban 10 mg orally once daily, based on a dosing schedule used for post-surgical clot prevention, or warfarin starting at 1.5 mg once daily with dose adjustments to maintain a target INR between 1.5 and 2.5. Warfarin dosing is carefully monitored with regular INR tests, initially after 3 days or 1 week, then weekly. Both drugs are given as preventive blood thinners to reduce the risk of blood clots during the study period. Throughout the six months, participants will be monitored for the occurrence of blood clots such as pulmonary embolism and deep vein thrombosis, as well as any bleeding events. Researchers will collect data on these outcomes to compare the safety and effectiveness of the two treatments. The trial includes regular blood tests and clinical assessments to ensure participant safety and to measure study endpoints. Total participation lasts six months from the start of prophylactic anticoagulation.

Rivaroxaban in Idiopathic Membranous Nephropathy